Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1622
This examiner grants 86% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18273491 | THERAPIES FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH ABNORMAL EXPRESSION OF CDKL5 GENE | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 19323352 | TREATMENT AND PREVENTION OF INFECTIONS USING VEGETABLE OIL-DERIVED POLYOLS | Non-Final OA | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES |
| 17686128 | COMPOSITIONS, METHODS AND USES FOR TARGETING C-TERMINAL BINDING PROTEIN (CtBP) IN TRAUMATIC BRAIN INJURY | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE |
| 17685892 | HISTONE DEACETYLASE AS A MODULATOR OF PDLI EXPRESSION AND ACTIVITY | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 18303813 | KRAS G12D MODULATING COMPOUNDS | Non-Final OA | Gilead Sciences, Inc. |
| 18283489 | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | Non-Final OA | Vicore Pharma AB |
| 18282426 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH HYPERMINERALIZATION | Non-Final OA | Université de Lausanne |
| 18025315 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | Non-Final OA | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 18467436 | NEK7 INHIBITORS | Non-Final OA | Halia Therapeutics, Inc. |
| 18208862 | DIPYRROLIDINE-1-ONE COMPOUNDS AND THEIR PREPARATION METHOD | Non-Final OA | Wuhan Jianmin Dapeng Pharmaceutical Co., Ltd. |
| 17777909 | METHODS OF ADMINISTERING VOXELOTOR | Final Rejection | Global Blood Therapeutics, Inc. |
| 17795402 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | Non-Final OA | Verastem, Inc. |
| 18095314 | Nutritional Intervention for Improving Muscular Function and Strength | Final Rejection | Metabolic Technologies, LLC |
| 17995413 | ADMINISTRATION OF mTOR INHIBITORS INTO THE CENTRAL NERVOUS SYSTEM | Non-Final OA | Diego Dolcetta |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy